Skip to content

Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer

Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer: A Multicenter Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06733766
Enrollment
300
Registered
2024-12-13
Start date
2024-12-09
Completion date
2030-12-31
Last updated
2025-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Thyroid Cancer

Brief summary

To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer

Detailed description

To evaluate and predict the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer by a multicenter study

Interventions

microwave ablation, radiofrequency ablation, laser ablation

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. patient received thyroidectomy for thyroid cancer 2. recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration 3. no evidence of distant metastases. 4. follow-up period ≥12 months

Exclusion criteria

1. coagulation disorder, serious heart, respiratory, liver, or renal failure 2. dysfunction of the vocal cord on the opposite side

Design outcomes

Primary

MeasureTime frameDescription
rate of disease progressionthrough study completion, an average of 6 monthscervical lymph node metastases and persistent tumors confirmed by pathology, Distant metastasis detected by CT, positron emission tomography, or bone scan if there were suspicious symptoms.

Secondary

MeasureTime frameDescription
rate of delayed surgerythrough study completion, an average of 1 yearpatients underwent surgery after ablation because of anxiety
rate of tumor disappearancethrough study completion, an average of 6 monthscomplete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound
Tg levelthrough study completion, an average of 6 monthsserum thyroglobulin level
rate of complications1 weekcomplication of ablation
rate of volume reductionthrough study completion, an average of 6 monthsvolume reduction of tumor after ablation on ultrasound and contrast-enhanced ultrasound

Countries

China

Contacts

Primary ContactLin Yan
gemma-y@163.com13811237313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026